Abstract
Focal Adhesion Kinase (FAK) plays an important role in cancer cell survival. Previous microarray gene profiling study detected inverse regulation between expression of thioredoxin-interacting protein (TXNIP) and FAK, where down-regulation of FAK by siRNA in MCF-7 cells caused up-regulation of TXNIP mRNA level, and in contrast up-regulation of doxycyclin- induced FAK caused repression of TXNIP. In the present report, we show that overexpression of FAK in MCF-7 cells repressed TXNIP promoter activity. Treatment of MCF-7 cells with 1alpha, 25-dihydroxyvitamin D3 (1,25D) down-regulated endogenous FAK and up-regulated TXNIP protein level, and treatment with 5-FU decreased FAK protein expression and up-regulated TXNIP protein expression in 293 cells. Moreover, silencing of FAK with siRNA increased TXNIP protein expression, while overexpression of FAK inhibited TXNIP protein expression in 293 cells. In addition, treatment of DBTRG glioblastoma cells with FAK inhibitor Y15 increased TXNIP mRNA, decreased cancer cell viability and increased apoptosis. These results for the first time demonstrate FAK-regulated TXNIP expression which is important for apoptotic, survival and oxidative stress signaling pathways in cancer cells.
Keywords: Apoptosis, brain cancer, breast cancer, focal adhesion kinase, thioredoxin-interacting protein.
Anti-Cancer Agents in Medicinal Chemistry
Title:Focal Adhesion Kinase Regulates Expression of Thioredoxin-interacting Protein (TXNIP) in Cancer Cells
Volume: 14 Issue: 1
Author(s): Baotran Ho, Grace Huang and Vita M. Golubovskaya
Affiliation:
Keywords: Apoptosis, brain cancer, breast cancer, focal adhesion kinase, thioredoxin-interacting protein.
Abstract: Focal Adhesion Kinase (FAK) plays an important role in cancer cell survival. Previous microarray gene profiling study detected inverse regulation between expression of thioredoxin-interacting protein (TXNIP) and FAK, where down-regulation of FAK by siRNA in MCF-7 cells caused up-regulation of TXNIP mRNA level, and in contrast up-regulation of doxycyclin- induced FAK caused repression of TXNIP. In the present report, we show that overexpression of FAK in MCF-7 cells repressed TXNIP promoter activity. Treatment of MCF-7 cells with 1alpha, 25-dihydroxyvitamin D3 (1,25D) down-regulated endogenous FAK and up-regulated TXNIP protein level, and treatment with 5-FU decreased FAK protein expression and up-regulated TXNIP protein expression in 293 cells. Moreover, silencing of FAK with siRNA increased TXNIP protein expression, while overexpression of FAK inhibited TXNIP protein expression in 293 cells. In addition, treatment of DBTRG glioblastoma cells with FAK inhibitor Y15 increased TXNIP mRNA, decreased cancer cell viability and increased apoptosis. These results for the first time demonstrate FAK-regulated TXNIP expression which is important for apoptotic, survival and oxidative stress signaling pathways in cancer cells.
Export Options
About this article
Cite this article as:
Ho Baotran, Huang Grace and Golubovskaya M. Vita, Focal Adhesion Kinase Regulates Expression of Thioredoxin-interacting Protein (TXNIP) in Cancer Cells, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (1) . https://dx.doi.org/10.2174/18715206113139990140
DOI https://dx.doi.org/10.2174/18715206113139990140 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Monoclonal Antibody “Gold Rush”
Current Medicinal Chemistry Synthesis, Biological and Computational Evaluation of Novel Oxindole Derivatives as Inhibitors of Src Family Kinases
Letters in Drug Design & Discovery Cucurbitacins as Inducers of Cell Death and a Rich Source of Potential Anticancer Compounds
Current Pharmaceutical Design Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells
Current Drug Targets Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part I
Inflammation & Allergy - Drug Targets (Discontinued) Single Nucleotide Polymorphisms in Colitis-Associated Colorectal Cancer: A Current Overview with Emphasis on the Role of the Associated Genes Products
Current Drug Targets TWIST1 Gene: First Insights in Felis catus
Current Genomics Mechanism of Action of Limonene in Tumor Cells: A Systematic Review and Meta-Analysis
Current Pharmaceutical Design Interaction of Probenecid with the Breast Cancer Resistance Protein Transporter (BCRP/ABCG2)
Letters in Drug Design & Discovery Peripheral Benzodiazepine Receptor (PBR) New Insight in Cell Proliferation and Cell Differentiation Review
Current Clinical Pharmacology Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis
Current Protein & Peptide Science A Pilot Study for Investigation of Plasma Amino Acid Profile in Neurofibromatosis Type 1 Patients
Combinatorial Chemistry & High Throughput Screening Design, Synthesis and Biological Evaluation of 5-Amino-1H-pyrazole-4- carboxamide Derivatives as Potential Antitumor Agents
Letters in Drug Design & Discovery Magnetic Resonance Imaging of the Cervix, and its Relevance to the Revised International Federation of Gynecology and Obstetrics (FIGO) Staging
Current Medical Imaging Complications Associated with Recombinant Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke
CNS & Neurological Disorders - Drug Targets Verification between Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC-MS Bioanalysis in Human Serum
Current Pharmaceutical Biotechnology Glucose Oncometabolism of Esophageal Cancer
Anti-Cancer Agents in Medicinal Chemistry Recent Patents on Devices and Technologies for Early Cancer Diagnostics
Recent Patents on Biomedical Engineering (Discontinued) Reversing Agents for ATP-Binding Cassette (ABC) Transporters: Application in Modulating Multidrug Resistance (MDR)
Current Medicinal Chemistry - Anti-Cancer Agents Patent Review
Combinatorial Chemistry & High Throughput Screening